178 related articles for article (PubMed ID: 15328108)
1. In vivo imaging of bioluminescent Escherichia coli in a cutaneous wound infection model for evaluation of an antibiotic therapy.
Jawhara S; Mordon S
Antimicrob Agents Chemother; 2004 Sep; 48(9):3436-41. PubMed ID: 15328108
[TBL] [Abstract][Full Text] [Related]
2. Monitoring of bactericidal action of laser by in vivo imaging of bioluminescent E. coli in a cutaneous wound infection.
Jawhara S; Mordon S
Lasers Med Sci; 2006 Sep; 21(3):153-9. PubMed ID: 16897111
[TBL] [Abstract][Full Text] [Related]
3. Validation of a noninvasive, real-time imaging technology using bioluminescent Escherichia coli in the neutropenic mouse thigh model of infection.
Rocchetta HL; Boylan CJ; Foley JW; Iversen PW; LeTourneau DL; McMillian CL; Contag PR; Jenkins DE; Parr TR
Antimicrob Agents Chemother; 2001 Jan; 45(1):129-37. PubMed ID: 11120955
[TBL] [Abstract][Full Text] [Related]
4. Cranberries vs antibiotics to prevent urinary tract infections: a randomized double-blind noninferiority trial in premenopausal women.
Beerepoot MA; ter Riet G; Nys S; van der Wal WM; de Borgie CA; de Reijke TM; Prins JM; Koeijers J; Verbon A; Stobberingh E; Geerlings SE
Arch Intern Med; 2011 Jul; 171(14):1270-8. PubMed ID: 21788542
[TBL] [Abstract][Full Text] [Related]
5. Ofloxacin versus trimethoprim/sulfamethoxazole in the treatment of uncomplicated urinary tract infection.
Cox CE; Serfer HS; Mena HR; Briefer C; Childs SJ; Gordon SF; Zoller JS
Clin Ther; 1992; 14(3):446-57. PubMed ID: 1638586
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of in vitro sensitivity testing methods of detecting sulphamethoxazole trimethoprim synergy. Correlation with mouse protection assay.
Rawal BD; Cottis L
Arzneimittelforschung; 1980; 30(7):1049-51. PubMed ID: 6998489
[TBL] [Abstract][Full Text] [Related]
7. In vitro resistance of E coli to TMP/SMX and clinical failure.
Postgrad Med; 2001 Aug; 110(2 Suppl):9-10; discussion 26-7. PubMed ID: 19667570
[No Abstract] [Full Text] [Related]
8. Urinary tract infection in women over the age of 65: is age alone a marker of complication?
Grover ML; Bracamonte JD; Kanodia AK; Edwards FD; Weaver AL
J Am Board Fam Med; 2009; 22(3):266-71. PubMed ID: 19429732
[TBL] [Abstract][Full Text] [Related]
9. Prevalence and predictors of trimethoprim-sulfamethoxazole resistance among uropathogenic Escherichia coli isolates in Michigan.
Brown PD; Freeman A; Foxman B
Clin Infect Dis; 2002 Apr; 34(8):1061-6. PubMed ID: 11914994
[TBL] [Abstract][Full Text] [Related]
10. Increasing in vitro resistance of E coli to TMP/SMX.
Postgrad Med; 2001 Aug; 110(2 Suppl):5-8; discussion 26-7. PubMed ID: 19667569
[No Abstract] [Full Text] [Related]
11. Clinical implications. In vitro resistance of E coli to TMP/SMX.
Postgrad Med; 2001 Aug; 110(2 Suppl):11-5; discussion 26-7. PubMed ID: 19667571
[No Abstract] [Full Text] [Related]
12. Susceptibility of antimicrobial-resistant urinary Escherichia coli isolates to fluoroquinolones and nitrofurantoin.
Karlowsky JA; Thornsberry C; Jones ME; Sahm DF
Clin Infect Dis; 2003 Jan; 36(2):183-7. PubMed ID: 12522750
[TBL] [Abstract][Full Text] [Related]
13. Antibacterial prophylaxis with trimethoprim-sulfamethoxazole during induction treatment for acute lymphoblastic leukemia.
Schrøder H; Agger KE; Rosthøj S; Carlsen NT; Schmiegelow K
Dan Med Bull; 2001 Nov; 48(4):275-7. PubMed ID: 11767129
[TBL] [Abstract][Full Text] [Related]
14. [Trimethoprim-sulfamethoxazole as antibacterial prophylaxis during induction therapy of children with acute lymphatic leukemia].
Agger KE; Schrøder H; Rosthøj S; Carlsen NT; Schmiegelow K
Ugeskr Laeger; 2002 Jan; 164(4):488-92. PubMed ID: 11838420
[TBL] [Abstract][Full Text] [Related]
15. Escherichia coli resistance in uncomplicated urinary tract infection: a model for determining when to change first-line empirical antibiotic choice.
Perfetto EM; Gondek K
Manag Care Interface; 2002 Jun; 15(6):35-42. PubMed ID: 12087605
[TBL] [Abstract][Full Text] [Related]
16. Characterization of Escherichia coli urinary tract infection isolates in remote northern Saskatchewan communities: the Northern Antibiotic Resistance Partnership.
Golding GR; Persaud N; Levett PN; McDonald RR; Irvine J; Nsungu M; Woods S; Khan M; Mataseje LF; Mulvey MR;
Diagn Microbiol Infect Dis; 2012 Nov; 74(3):242-7. PubMed ID: 22944458
[TBL] [Abstract][Full Text] [Related]
17. Use of a bioluminescent Pseudomonas aeruginosa strain within an in vitro microbiological system, as a model of wound infection, to assess the antimicrobial efficacy of wound dressings by monitoring light production.
Thorn RM; Nelson SM; Greenman J
Antimicrob Agents Chemother; 2007 Sep; 51(9):3217-24. PubMed ID: 17638701
[TBL] [Abstract][Full Text] [Related]
18. Uncomplicated E. coli urinary tract infection in college women: a follow-up study of E. coli sensitivities to commonly prescribed antibiotics.
Ansbach RK; Dybus K; Bergeson R
J Am Coll Health; 2005; 54(2):81-4; discussion 85-6. PubMed ID: 16255319
[TBL] [Abstract][Full Text] [Related]
19. Empiric use of trimethoprim-sulfamethoxazole (TMP-SMX) in the treatment of women with uncomplicated urinary tract infections, in a geographical area with a high prevalence of TMP-SMX-resistant uropathogens.
Raz R; Chazan B; Kennes Y; Colodner R; Rottensterich E; Dan M; Lavi I; Stamm W;
Clin Infect Dis; 2002 May; 34(9):1165-9. PubMed ID: 11941541
[TBL] [Abstract][Full Text] [Related]
20. Pediatric-specific antimicrobial susceptibility data and empiric antibiotic selection.
Boggan JC; Navar-Boggan AM; Jhaveri R
Pediatrics; 2012 Sep; 130(3):e615-22. PubMed ID: 22891227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
